The AbC-19™ Rapid Test is able to confirm that IgG antibodies to the full Spike protein have been produced after vaccination or following direct exposure to the SARS-CoV-2 virus.
The AbC-19™ Rapid Test can be deployed across multiple populations and has the potential to inform vaccination programmes and health policy. The test can do this by showing how COVID-19 infection spreads through communities, where any why immunity to COVID-19 might be developing and how mass-immunisation campaigns could be designed.
The AbC-19™ Rapid Test is delivered at point of care (POC) using a blood sample from a finger-stick puncture, with test results ready in just 20 minutes.
Why use the AbC-19™ Rapid Test?